This page provides up to date resources for ARM members managing research, development, operations, finance, or other aspects of their mission in the midst of the COVID-19 pandemic.
Management of Clinical Trials During COVID-19
Information on COVID-19 and Ongoing Clinical Trials
Support for the Liquidity of Households and Businesses Through the Banking System
Queries and Frequently Asked Questions About Industry and SMEs
In response to the ongoing global spread of COVID-19 (coronavirus), several academic research centers and therapeutic developers have announced that they are investigating the application of regenerative medicine technologies treat this disease in the short term and address related complications in the future. Approaches may include therapies intended to promote immune response and manage inflammatory responses in patients with the disease, as well as approaches to repair tissues damaged by the disease in the long-term.
As always, patient health and safety is paramount. There are currently no approved treatments for coronavirus, and patients should avoid unproven and potentially harmful therapies marketed by practitioners without the appropriate regulatory oversight provided by the clinical trial process. Click here for ARM’s position on the regulation of stem cell therapeutic candidates.
Cellenkos Focuses on the Development of Cell Therapy for Treatment of CoV-ARDS
NantKwest and ImmunityBio Announce Therapeutics and Vaccines for Combatting COVID-19
Webinar: How Business, Workers and Workplaces Should Respond to COVID-19
